预测肾输尿管切除术后肾功能的多变量列线图的开发与验证
本研究为多机构回顾性研究,纳入2000至2020年在七家高容量转诊中心接受根治性肾输尿管切除术(RNU)的1100例上尿路尿路上皮癌(UTUC)患者,按2:1随机分为发现队列(733例)和验证队列(367例)。基于线性回归与后退法构建的多变量列线图预测术后1-3个月eGFR,在发现队列和验证队列中的准确率分别为80.5%和78.6%。
要点
- 列线图纳入年龄、糖尿病、高血压、肿瘤大小和术前eGFR等常规术前变量,预测RNU术后1-3个月eGFR。
- 预测准确率在发现队列为80.5%,在验证队列为78.6%(定义为预测eGFR落在实测值±30%以内的比例)。
- 研究排除了接受新辅助化疗的患者,作者结论为列线图可用于预测术后eGFR并经独立队列验证。
核心结论
- 基于常规术前临床变量的列线图可预测RNU术后eGFR,并在独立队列中得到验证。
研究设计与样本
- 多机构回顾性研究,纳入2000至2020年七家高容量转诊中心接受RNU的UTUC患者1100例,按2:1随机分为发现队列733例和验证队列367例。
- 在发现队列中以线性回归识别与RNU术后1-3个月GFR相关的独立因素,并采用后退法构建模型。
- 准确率定义为预测eGFR落在相应实测eGFR±30%以内的百分比。
主要发现
- 术后eGFR下降的多变量预测因素包括高龄(OR -0.18,95%CI -0.28至-0.08)、糖尿病(OR -2.38,95%CI -4.64至-0.11)和高血压(OR -2.24,95%CI -4.16至-0.32)。
- 与术后eGFR较好相关的因素包括较大肿瘤(>5 cm vs ≤2 cm:OR 10.57,95%CI 7.4-13.74)和术前eGFR(OR 0.44,95%CI 0.39-0.49)。
- 复合列线图预测术后eGFR的准确率在发现队列为80.5%,在验证队列为78.6%。
关键数值与推荐
- 高龄OR -0.18(95%CI -0.28至-0.08)、糖尿病OR -2.38(95%CI -4.64至-0.11)、高血压OR -2.24(95%CI -4.16至-0.32)与术后eGFR下降相关。
- 肿瘤>5 cm vs ≤2 cm的OR为10.57(95%CI 7.4-13.74),术前eGFR的OR为0.44(95%CI 0.39-0.49),均与术后eGFR较好相关。
- 列线图预测准确率:发现队列80.5%,验证队列78.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究排除了接受新辅助化疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The timing of perioperative nephrotoxic chemotherapy for upper tract urothelial carcinoma (UTUC) remains controversial and strongly depends on predicted platinum eligibility after radical nephroureterectomy (RNU). The study objective was to develop and validate a multivariable nomogram to predict estimated glomerular filtration rate (eGFR) following RNU. METHODS: This was a multi-institutional retrospective study of patients with UTUC treated with RNU from 2000 to 2020 at seven high-volume referral centers. Use of adjuvant chemotherapy was risk-stratified. Patients were retrospectively randomly allocated 2:1 to discovery and validation cohorts. Discovery data were used to identify independent factors associated with GFR at 1-3 mo after RNU on linear regression, and backward selection was applied for model construction. Accuracy was defined as the percentage of predicted eGFR results within 30% of the corresponding observed eGFR. KEY FINDINGS AND LIMITATIONS: We included 1100 patients, of whom 733 were in the discovery and 367 were in the validation cohort. Multivariable predictors of postoperative eGFR decline included advanced age (odds ratio [OR] -0.18, 95% confidence interval [CI] -0.28 to -0.08), diabetes (OR -2.38, 95% CI -4.64 to -0.11), and hypertension (OR -2.24, 95% CI -4.16 to -0.32). Factors associated with favorable postoperative eGFR included larger tumor size (OR 10.57, 95% CI 7.4-13.74 for tumors >5 cm vs ≤2 cm) and preoperative eGFR (OR 0.44, 95% CI 0.39-0.49). A composite nomogram predicted postoperative eGFR with good accuracy in both the discovery (80.5%) and validation (78.6%) cohorts. Limitations include exclusion of patients who received neoadjuvant chemotherapy. CONCLUSIONS: A nomogram that incorporates ubiquitous preoperative clinical variables can predict post-RNU eGFR and was validated with an independent cohort. PATIENT SUMMARY: We developed a tool that uses patient data to predict eligibility for chemotherapy after surgery to remove the kidney and ureter in patients with cancer in the upper urinary tract.
引用
- Hensley PJ, Labbate C, Zganjar A, et al. Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function. Eur Urol Oncol. 2024. PMID: 38307832. doi:10.1016/j.euo.2024.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。